Ying Wen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ying Wen has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Wen Wang
The Second Department of Infectious Diseases, The First Affiliated Hospital of China Medical University
8 shared publicationsYing Zhou
Department of Infectious Diseases II, Shenyang Natural Focal Diseases Clinical Medical Research Center, The First Affiliated Hospital of China Medical University. No. 155, Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province, China
8 shared publicationsJun Yang
Neurology Department, The First Affiliated Hospital of China Medical University
7 shared publicationsSheng Liu
The First Affiliated Hospital of China Medical University
5 shared publicationsYanli Wang
Department of Infectious Diseases II, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
5 shared publicationsYu Wang
The First Affiliated Hospital of China Medical University
5 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1982338
Epstein-Barr virus and hepatic failure: pathogenesis, clinical manifestations, and management
Epstein-Barr virus (EBV) infection is ubiquitous, affecting over 90% of the global population, and while typically benign, it can rarely cause acute liver failure — a life-threatening complication that is frequently fatal. This review comprehensively reviews two overlapping clinical and pathogenetic patterns of EBV-associated hepatic failure — isolated severe EBV hepatitis and EBV-triggered hemophagocytic lymphohistiocytosis (HLH) — which are best understood as ends of a clinical spectrum rather than discrete entities. In isolated EBV hepatitis, liver injury is driven by CD8-positive T cells attacking EBV-infected B cells, causing bystander hepatocyte necrosis; inflammation remains confined to the liver, and supportive care is usually sufficient. By contrast, EBV-HLH involves EBV-infected monoclonal T or natural killer cells triggering a systemic cytokine storm (including interferon-gamma, tumor necrosis factor-alpha, interleukin-6, and interleukin-18) with hemophagocytosis, requiring immediate immunosuppression. In one pediatric cohort, an EBV DNA load exceeding 100,000 copies per milliliter was associated with a more than ten-fold increase in mortality, although no universally validated cutoff has been established across age groups or sample types; T-cell EBV DNA load provides additional prognostic information. Blood purification is an experimental adjunctive strategy in refractory cases, supported by very low-certainty evidence. We also discuss risk factors, diagnostic algorithms (including EBV DNA load, HLH-2004 criteria, and histopathology), therapeutic strategies (supportive care, antiviral therapy, immunomodulation, and liver transplantation), and future research priorities. Early recognition of HLH is life-saving. This review provides a practical clinical framework for differentiating these two entities and highlights knowledge gaps for future investigation.
- 25 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1982338
Open AccessEpstein-Barr virus and hepatic failure: pathogenesis, clinical manifestations, and management
Epstein-Barr virus (EBV) infection is ubiquitous, affecting over 90% of the global population, and while typically benign, it can rarely cause acute liver failure — a life-threatening complication that is frequently fatal. This review comprehensively reviews two overlapping clinical and pathogenetic patterns of EBV-associated hepatic failure — isolated severe EBV hepatitis and EBV-triggered hemophagocytic lymphohistiocytosis (HLH) — which are best understood as ends of a clinical spectrum rather than discrete entities. In isolated EBV hepatitis, liver injury is driven by CD8-positive T cells attacking EBV-infected B cells, causing bystander hepatocyte necrosis; inflammation remains confined to the liver, and supportive care is usually sufficient. By contrast, EBV-HLH involves EBV-infected monoclonal T or natural killer cells triggering a systemic cytokine storm (including interferon-gamma, tumor necrosis factor-alpha, interleukin-6, and interleukin-18) with hemophagocytosis, requiring immediate immunosuppression. In one pediatric cohort, an EBV DNA load exceeding 100,000 copies per milliliter was associated with a more than ten-fold increase in mortality, although no universally validated cutoff has been established across age groups or sample types; T-cell EBV DNA load provides additional prognostic information. Blood purification is an experimental adjunctive strategy in refractory cases, supported by very low-certainty evidence. We also discuss risk factors, diagnostic algorithms (including EBV DNA load, HLH-2004 criteria, and histopathology), therapeutic strategies (supportive care, antiviral therapy, immunomodulation, and liver transplantation), and future research priorities. Early recognition of HLH is life-saving. This review provides a practical clinical framework for differentiating these two entities and highlights knowledge gaps for future investigation.
- Open Access
- 9 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13
Case Report: The complete radiological resolution of diffuse cholangitis in a HIV-positive patient with cryptosporidium infection after anti-retroviral therapy
We present a case of an HIV-positive patient with AIDS cholangiopathy secondary to Cryptosporidium infection. Imaging examination showed intrahepatic and extrahepatic cholangitis without papillary stenosis and extrahepatic bile duct strictures, indicating mild bile duct disease. However, it failed to obtain positive results in fecal microscopy examinations. Alternatively, metagenomic next-generation sequencing (mNGS) of a blood sample identified Cryptosporidium infection. The diagnostic power of mNGS is highly sensitive and can simultaneously identify various pathogens. To avoid irreversible damage to the biliary system, the rapid initiation of anti-HIV therapy restored the function of the immune system and led to the clinical resolution of cryptosporidiosis.
- 9 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13
Open AccessCase Report: The complete radiological resolution of diffuse cholangitis in a HIV-positive patient with cryptosporidium infection after anti-retroviral therapy
We present a case of an HIV-positive patient with AIDS cholangiopathy secondary to Cryptosporidium infection. Imaging examination showed intrahepatic and extrahepatic cholangitis without papillary stenosis and extrahepatic bile duct strictures, indicating mild bile duct disease. However, it failed to obtain positive results in fecal microscopy examinations. Alternatively, metagenomic next-generation sequencing (mNGS) of a blood sample identified Cryptosporidium infection. The diagnostic power of mNGS is highly sensitive and can simultaneously identify various pathogens. To avoid irreversible damage to the biliary system, the rapid initiation of anti-HIV therapy restored the function of the immune system and led to the clinical resolution of cryptosporidiosis.
- Open Access
- 30 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1805701
Individualized immunotherapy for immune reconstitution-associated cortical encephalitis in an HIV-positive cryptococcal meningitis patient: a case report
Background: Neurological immune reconstitution inflammatory syndrome (IRIS) in HIV can present variably. We report a case of steroid-dependent, recurrent cortical encephalitis with a distinctive migratory Magnetic Resonance Imaging (MRI) pattern following cryptococcal meningitis. Case presentation: A 38-year-old male with advanced HIV (CD4 11/μL) developed cryptococcal meningitis. After antifungal induction and switching to effective antiretroviral therapy (bictegravir/emtricitabine/tenofovir alafenamide), he suffered recurrent neurological episodes. Serial brain MRIs showed sequentially appearing and resolving T2/Fluid-Attenuated Inversion Recovery (FLAIR) hyperintensities in the bilateral frontal lobes, left cingulate gyrus, and left occipital cortex, despite negative infectious and autoimmune workup. Symptoms were steroid-responsive but relapsed upon tapering. Lasting remission was achieved only after adding mycophenolate mofetil (MMF), allowing corticosteroid withdrawal. Conclusions: This case describes a “migratory cortical encephalitis” phenotype of Central Nervous System (CNS)-IRIS. It highlights that cortical grey matter can be the primary target in severe IRIS and illustrates the utility of steroid-sparing agents like MMF for managing refractory, steroid-dependent neuroinflammation in this context.
- 30 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1805701
Open AccessIndividualized immunotherapy for immune reconstitution-associated cortical encephalitis in an HIV-positive cryptococcal meningitis patient: a case report
Background: Neurological immune reconstitution inflammatory syndrome (IRIS) in HIV can present variably. We report a case of steroid-dependent, recurrent cortical encephalitis with a distinctive migratory Magnetic Resonance Imaging (MRI) pattern following cryptococcal meningitis. Case presentation: A 38-year-old male with advanced HIV (CD4 11/μL) developed cryptococcal meningitis. After antifungal induction and switching to effective antiretroviral therapy (bictegravir/emtricitabine/tenofovir alafenamide), he suffered recurrent neurological episodes. Serial brain MRIs showed sequentially appearing and resolving T2/Fluid-Attenuated Inversion Recovery (FLAIR) hyperintensities in the bilateral frontal lobes, left cingulate gyrus, and left occipital cortex, despite negative infectious and autoimmune workup. Symptoms were steroid-responsive but relapsed upon tapering. Lasting remission was achieved only after adding mycophenolate mofetil (MMF), allowing corticosteroid withdrawal. Conclusions: This case describes a “migratory cortical encephalitis” phenotype of Central Nervous System (CNS)-IRIS. It highlights that cortical grey matter can be the primary target in severe IRIS and illustrates the utility of steroid-sparing agents like MMF for managing refractory, steroid-dependent neuroinflammation in this context.
- Open Access
- 29 March 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2650232
The role of systemic inflammation in hepatic encephalopathy: advances in inflammatory mechanisms, prevention and treatment research
1. Hepatic encephalopathy (HE) refers to a range of neuropsychiatric impairments resulting from liver dysfunction or portosystemic shunts. Its clinical presentation is marked by disturbances in cog...
- 29 March 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2650232
Open AccessThe role of systemic inflammation in hepatic encephalopathy: advances in inflammatory mechanisms, prevention and treatment research
1. Hepatic encephalopathy (HE) refers to a range of neuropsychiatric impairments resulting from liver dysfunction or portosystemic shunts. Its clinical presentation is marked by disturbances in cog...
- Open Access
- 29 December 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 164, 108361
A case of HIV encephalopathy with HIV cerebrospinal fluid escape, followed by second-generation integrase inhibitor resistance
- 29 December 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 164, 108361
Open AccessA case of HIV encephalopathy with HIV cerebrospinal fluid escape, followed by second-generation integrase inhibitor resistance
- Open Access
- 20 October 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1674188
Pure red cell aplasia post-SARS-CoV-2 infection: a case report in an HIV-positive patient
We present a case of Pure Red Cell Aplasia (PRCA) secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a human immunodeficiency virus (HIV)-positive patient. To our knowledge, this is the first reported case of SARS-CoV-2-associated PRCA in an HIV-positive individual. The patient received immunosuppressive therapy (IST):initial treatment with corticosteroids was later switched to cyclosporine A (CsA), and he ultimately achieved complete remission. Additionally, we reviewed previously reported cases of SARS-CoV-2-associated PRCA. These findings emphasize that hematological abnormalities should also be recognized as a critical extrapulmonary complication of SARS-CoV-2 infection. In conclusion, SARS-CoV-2 infection can affect bone marrow tissue, leading to a spectrum of hematological abnormalities and subsequent clinical sequelae. For HIV-positive patients presenting with PRCA, antiretroviral drugs and acute or chronic infections should be prioritized in the diagnostic workup.
- 20 October 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1674188
Open AccessPure red cell aplasia post-SARS-CoV-2 infection: a case report in an HIV-positive patient
We present a case of Pure Red Cell Aplasia (PRCA) secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a human immunodeficiency virus (HIV)-positive patient. To our knowledge, this is the first reported case of SARS-CoV-2-associated PRCA in an HIV-positive individual. The patient received immunosuppressive therapy (IST):initial treatment with corticosteroids was later switched to cyclosporine A (CsA), and he ultimately achieved complete remission. Additionally, we reviewed previously reported cases of SARS-CoV-2-associated PRCA. These findings emphasize that hematological abnormalities should also be recognized as a critical extrapulmonary complication of SARS-CoV-2 infection. In conclusion, SARS-CoV-2 infection can affect bone marrow tissue, leading to a spectrum of hematological abnormalities and subsequent clinical sequelae. For HIV-positive patients presenting with PRCA, antiretroviral drugs and acute or chronic infections should be prioritized in the diagnostic workup.
- Open Access
- 23 April 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1556041
Successful treatment of pulmonary hypertension due to HIV infection and amphetamine snorting: a case report
HIV infection is one of the high-risk factors for pulmonary hypertension (PH). HIV-related PH is associated with non-AIDS-related comorbidities. In this study, we report a case of pulmonary hypertension with several concomitant risk factors who experienced a complete clinical improvement after drug rehabilitation, application of anti-retroviral therapy (ART), and sildenafil. A 37-year-old HIV-positive man complained about worsening dyspnea was diagnosed with severe PH. PH in this case was characterized by association with multi-factors, including amphetamine inhalation, HIV infection, bacterial liver abscess, history of splenectomy, and past ventricular septal defect, which was different from previously reported HIV-related PH cases who were associated solely with HIV infection. Our case intends to raise awareness that PH should be suspected among HIV-positive patients with unexplained dyspnea. It is notable that investigating the coexistent risk factors and a multidisciplinary team are crucial for early diagnosis and better prognosis of HIV-related PH.
- 23 April 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1556041
Open AccessSuccessful treatment of pulmonary hypertension due to HIV infection and amphetamine snorting: a case report
HIV infection is one of the high-risk factors for pulmonary hypertension (PH). HIV-related PH is associated with non-AIDS-related comorbidities. In this study, we report a case of pulmonary hypertension with several concomitant risk factors who experienced a complete clinical improvement after drug rehabilitation, application of anti-retroviral therapy (ART), and sildenafil. A 37-year-old HIV-positive man complained about worsening dyspnea was diagnosed with severe PH. PH in this case was characterized by association with multi-factors, including amphetamine inhalation, HIV infection, bacterial liver abscess, history of splenectomy, and past ventricular septal defect, which was different from previously reported HIV-related PH cases who were associated solely with HIV infection. Our case intends to raise awareness that PH should be suspected among HIV-positive patients with unexplained dyspnea. It is notable that investigating the coexistent risk factors and a multidisciplinary team are crucial for early diagnosis and better prognosis of HIV-related PH.
- Open Access
- 28 March 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2484666
Regarding: research progress of femoral head necrosis in HIV-infected patients
- 28 March 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2484666
Open AccessRegarding: research progress of femoral head necrosis in HIV-infected patients
- Open Access
- 11 March 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1537160
Successfully salvaging a HIV-positive patient with mixed CIDP and meningoencephalitis: a case report
We describe an acquired immunodeficiency syndrome (AIDS) patient who first exhibited chronic inflammatory demyelinating polyneuropathy (CIDP) and subsequently developed meningoencephalitis due to ganciclovir (GCV)-resistant cytomegalovirus (CMV) infection. The patient first presented with peripheral nervous system (PNS) symptoms, followed by central nervous system (CNS) symptoms. Based on auxiliary examinations, including cerebrospinal fluid (CSF) tests, electromyography (EMG), brain magnetic resonance imaging (MRI) and GCV drug resistance tests, the patient was diagnosed with CIDP and meningoencephalitis due to CSF GCV-resistant CMV. After the combined application of intravenous immunoglobulin treatment, corticosteroid treatment, antiretroviral therapy (ART), and adjusted anti-CMV treatment, the patient achieved persistent relief. This case underscores the importance of considering CMV as a common etiology of neurological disorders in AIDS patients. It also highlights the necessity of prompt drug resistance testing when anti-CMV therapy yields suboptimal responses.
- 11 March 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1537160
Open AccessSuccessfully salvaging a HIV-positive patient with mixed CIDP and meningoencephalitis: a case report
We describe an acquired immunodeficiency syndrome (AIDS) patient who first exhibited chronic inflammatory demyelinating polyneuropathy (CIDP) and subsequently developed meningoencephalitis due to ganciclovir (GCV)-resistant cytomegalovirus (CMV) infection. The patient first presented with peripheral nervous system (PNS) symptoms, followed by central nervous system (CNS) symptoms. Based on auxiliary examinations, including cerebrospinal fluid (CSF) tests, electromyography (EMG), brain magnetic resonance imaging (MRI) and GCV drug resistance tests, the patient was diagnosed with CIDP and meningoencephalitis due to CSF GCV-resistant CMV. After the combined application of intravenous immunoglobulin treatment, corticosteroid treatment, antiretroviral therapy (ART), and adjusted anti-CMV treatment, the patient achieved persistent relief. This case underscores the importance of considering CMV as a common etiology of neurological disorders in AIDS patients. It also highlights the necessity of prompt drug resistance testing when anti-CMV therapy yields suboptimal responses.
- Open Access
- 1 August 2024
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 16 (8) , 5484-5486
Open questions between immune checkpoint inhibitors and tuberculosis incidence
Open questions between immune checkpoint inhibitors and tuberculosis incidence
- 1 August 2024
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 16 (8) , 5484-5486
Open AccessOpen questions between immune checkpoint inhibitors and tuberculosis incidence
Open questions between immune checkpoint inhibitors and tuberculosis incidence